Aims To study the diagnostic value of a new 2D left ventricle hypertrophy (2D LVH) score in families with hypertrophic cardiomyopathy (HCM) in comparison with the conventional maximal wall thickness (MWT) measurement (.13 mm in adults), which is limited by a low sensitivity in relatives.
Introduction
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder 1 characterized by hypertrophy of the left ventricle, whose affected wall is usually the interventricular septum. 2 Its diagnosis, based on ECG and/or echocardiographic criteria, is of critical importance because of the risk of sudden death in young adults and especially in young athletes. 3 The major echocardiographic diagnostic criterion remains the maximal wall thickness (MWT) measurement whose diagnostic value in relatives of a proband is limited because of low sensitivity. 4 The use of Devereux's mass index is probably limited in this disease because of the asymmetrical extent of hypertrophy in HCM. 5 Spirito and Maron 6,7 described a 2D left ventricular hypertrophy (LVH) score which is the sum of the MWT obtained in four LV segments at basal or midventricular level. It is a quantitative hypertrophy score whose accuracy in HCM was validated in echocardiography vs. MRI. 8, 9 However, its diagnostic value in HCM is still unknown and remains to be studied. The aims of this study were (i) to compare the diagnostic value of a 2D LVH echo score, using a new cut-off value corrected for age, sex, and body surface area (BSA) in each individual, with the conventional MWT measurement in an adult HCM genotyped population (derivation sample) and (ii) to validate prospectively these results in a second HCM genotyped population (validation sample).
Methods Patients
All first degree relatives from 18 families in which the mutation responsible was previously identified [10] [11] [12] were proposed to be & The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org included in the study. The population consisted of 237 adults (.18 years) and was divided in two populations based on chronological recruitment. One-hundred and nine adults constituted the derivation sample (population A, n ¼ 109). All subjects were from seven families affected by HCM with seven distinct mutations concerning three different genes (MYH7, MYBPC3, and MYL2 ). Each individual was genotyped: 55 individuals were genetically healthy (55 Mu2) and 54 were carriers of a mutation (54 Muþ).
One-hundred and twenty eight adults constituted the validation sample (population B, n ¼ 128). The subjects were from 11 families affected by HCM with nine distinct mutations concerning four different genes (MYBPC3, MYH7, TNNI3, and TNNT2 ). Forty-five adults were healthy (45 Mu2) and 83 were affected (83 Muþ).
Echocardiography
Echo was performed at the time of genotyping by the referent cardiologist according to a standardized procedure. 13 M-mode, 2D, and Doppler echocardiographic examinations were performed using a 2.5 or 3.5 MHz transducer in standard parasternal long-axis, shortaxis, apical four-and two-chamber views and were recorded on VHS videotape. Five patients with a poor echogenicity were excluded from the study and represented 2% (5/242) of the total population.
The next time, videotapes were independently and successively read by two experts (from J.F.F., P.C., and O.D.) who were blind to the genotype. Mean values of the three measurements were calculated. In case of discrepancies, echos were reviewed by a third expert and a final agreement was achieved by the three experts.
MWTwas measured in 2D echocardiography. 4, 6, 13 To determine the hypertrophy score proposed by Spirito and Maron (2D LVH score), the left ventricle was divided into four segments corresponding to the anterior and posterior ventricular septum and the anterolateral and posterior left ventricular free walls. 7 The 2D LVH score is the sum of the measurements of MWT obtained in each of the four left ventricular segments. MWT for each segment was defined as the greatest thickness identified in the basal (mitral valve) or midventricular (papillary muscles) short-axis planes in any of the four segments ( Figure 1 ) .
Two different echo criteria were analysed as diagnostic tools: the conventional one, where MWT .13 mm; and the 2D LVH score using an adjusted cut-off value determined by multiple linear regression analysis. The fit of the regression models was evaluated by testing the residuals for normality and by inspecting the residual plots.
Statistical analysis
Mean values for continuous parameters were compared using Student's t-test. Categorial parameters were compared using the x 2 test. Sensitivities were compared using exact McNemar's test. A comparison of sensitivities in the subgroup of youngest subjects (,50 years) was planned. The penetrance of the disease is agerelated and the subgroup of young subjects is characterized by the lowest sensitivity. Thus, the need for new diagnostic parameters is particularly important in this specific subgroup.
Tests were two-sided and a P-value ,0.05 was considered as significant.
The adjustment of the LVH score in the derivation population was performed by multiple linear regression analysis, including age, sex, and BSA as covariables. These parameters were chosen because they are involved in the variability of LV mass. 14 We confirmed the involvement of these parameters in the variability of the 2D score and included them in the definition of the theoretical 2D score.
A cut-off value for the LVH score was subsequently determined according to a receiver operating characteristic (ROC) curve analysis, with a specificity set at 95% and to maximize sensitivity.
Results
Clinical features of the two populations are summarized in Table 1 . In the derivation population (population A), we observed that the 2D LVH score was significantly different between the mutation carriers group and the non-carriers group (51.7 + 15.9 vs. 36.3 + 4.5 mm, P , 0.0001).
Definition of the adjusted LVH score
Definition of a theoretical LVH score in controls of the derivation sample In the healthy derivation sample (Mu2), 2D LVH score was significantly influenced in linear logistic regression analysis by age (P ¼ 0.002), sex (P ¼ 0.04), and BSA (P ¼ 0.05). After multiple linear regression analysis, a new theoretical score was defined in each individual as follows (standard error of the mean predict: 0.84): theoretical LVH score (in mm) ¼ 18.95 þ (0.12 Â age) þ (2.64 Â sex) þ (6.41 Â BSA) with sex (¼1 in men and 0 in women), age in years, and BSA in kg/m 2 . Definition of affected individuals using a theoretical LVH score Observed LVH scores were compared with theoretical LVH scores in the total derivation population. The difference between the two values was computed. Cut-off values were defined by ROC analysis to obtain a specificity of 95% and to maximize sensitivity for diagnosis. The optimal difference between observed and theoretical scores was found to be 5 mm ( Figure 2 ). In other terms, an individual was clinically affected if the observed LVH score was greater than (theoretical score þ5 mm).
Diagnostic value of hypertrophy scores
The diagnostic value of MWT and 2D LVH score was studied in the derivation sample (population A, n ¼ 109). The results are summarized in Table 2 . Sensitivity of MWT was poor (62.5%) as previously described. 4 Specificity was 100%. In the LVH score, there was an increase in sensitivity of 10.5% (Se ¼ 73%, P , 0.04 vs. MWT), with specificity remaining good (Sp ¼ 96%). When we analysed the diagnostic value of these hypertrophy scores in the subgroup of young adults (age between 18 and 49, n ¼ 81 individuals, Table 2 ), sensitivity of MWT was poor (54%). Using the 2D LVH score, the increase in sensitivity was large (Se ¼ 69%, þ15%) (P , 0.04 for the comparison between MWT and 2D LVH), and specificity was still good (Sp ¼ 98%).
The accuracy of the theoretical LVH score was confirmed in the validation sample (population B, n ¼ 128, Table 3 ). Sensitivity was equal to 75% (vs. 73% in the population A) with good specificity (96%, identical in population A). In comparison with MWT, sensitivity of the LVH score increased significantly by 11% (75 vs. 64%, P , 0.03). When the analysis was restricted to the subgroup of young adults, the diagnostic value of the LVH score remained good with a sensitivity of 67% (vs. 69% in the subgroup A) and a specificity of 97% (vs. 98% in the subgroup A). Gain of sensitivity in comparison with MWT was confirmed and significant (67 vs. 53%, P , 0.03).
Discussion
We report here for the first time the diagnostic value of an echocardiographic 2D LVH score for familial HCM. The extent and quantification of hypertrophy in HCM are well determined by Scan Imatron 15 or MRI, 16 ,17 but these are not routinely available for diagnosis. Thus, along with ECG, echocardiography remains the most useful tool for screening of a population.
However, the diagnostic value of the conventional major echo criterion (MWT .13 mm) is limited by poor sensitivity, previously estimated at 62% in an adult genotyped population. 4 The reasons of this low sensitivity are probably various. The first reason may be related to the intrinsic limitations of the technique by itself: imaging of the myocardium hampered by limited windows or adjacent lung tissue; frequently abrupt change in thickness observed in HCM which is not a problem for MRI imaging; and insufficient echogenicity to allow adequate delineation of endocardial and epicardial borders in all regions of the LV, in particular at the apex or the anterolateral wall level. 18 Indeed, when compared with echocardiography in HCM, MRI allowed a better assessment of the number of affected Figure 2 Definition of an adjusted 2D LVH score for HCM by comparing observed and theoretical scores in the derivation population (population A), according to ROC analysis. The cut-off value to maximize the sensitivity at a specificity near 95% was found to be the theoretical score þ5 mm (sensitivity 73%, specificity 96%).
segments of the LV and a better visualization of the anterolateral wall. 9 The second reason may be related to the true absence of hypertrophy in a subset of patients because of the age-related penetrance of the mutations. 19 Indeed, the diagnostic accuracy of echo was shown to increase with age: 4 in this study, sensitivity of the conventional echo criterion was 43% in a first age group between 18 and 29, 68% in a second age group between 30 and 49, and finally increased to 83% in a third age group .50. In our work, sensitivity of MWT in the subgroup ,50 years was only 54% and reinforces the previous results. The reasons for the influence of age on the penetrance of mutations remain unclear.
We hypothesized that a 2D LVH hypertrophy score could be useful and more accurate than a single wall thickness measurement for the diagnosis of HCM, because it evaluates the extent of hypertrophy at eight different segments of the myocardium. In accordance with previously established variables influencing LV mass, 14, 20 we demonstrated that the 2D LVH score was significantly influenced by age, sex, and BSA in the control population. We then defined for each individual an adjusted value for the score using a multiple linear regression model and a theoretical cut-off value using ROC analysis. We found that sensitivity of this 2D LVH score was better than that of the conventional criterion, whereas the specificity remained very good. Moreover, in the young population where sensitivity of MWT is low (54%), when we used the 2D LVH score, sensitivity significantly increased by 15% (P , 0.04) in the derivation sample and this was confirmed in the validation sample (þ14%, P , 0.03). In our model, the adjusted 2D LVH score incorporated age, sex, and BSA which are modifying factors of LV mass. This may also explain why a theoretical cut-off value, which incorporates those parameters, is more accurate than a single wall measurement.
It is of critical importance to increase the sensitivity of diagnostic criteria for HCM. First, the molecular process of identification of the mutation responsible in a family is long, expensive, and uncertain and is available in only few institutions. Because of a wide genetic heterogeneity of the disease (11 different genes and more than 220 causal mutations), 12 at least several months are required to identify the responsible mutation. 21 This is why the improvement of HCM clinical diagnostic criteria is crucial in order to improve the assessment of phenotypic status in relatives. Secondly, this improvement of cardiological tools would allow the detection of 'healthy carriers', who are genetically affected but are not detected by conventional ECG and echo criteria (30% of genetically affected individuals). 4 This would therefore lead to the early identification of subjects at high risk of developing the disease later. 4, 22 Such 'borderline' subjects, with normal conventional criteria but with an abnormal 2D LVH score, have a pre-clinical HCM, which is an intermediate step between totally healthy carriers and HCM patients. These subjects should benefit from a medical follow-up, with regular clinical assessment, possibly less frequently than patients with obvious HCM but more frequently than subjects carrying a mutation without any cardiac abnormalities. 23 The diagnosis of HCM is usually based on the morphologic abnormalities and this is the reason why we focused our work on the expression of hypertrophy. However, the phenotypic expression of HCM is a very complex process including ventricular functional abnormalities (diastolic abnormalities), morphologic abnormalities (LV hypertrophy with or without obstruction, mitral valve abnormalities), and electrogenesis (fibrosis, atrial, and ventricular arythmias). 24 It is possible that the early diagnosis of HCM may benefit from the analysis of the functional or electrophysiological aspects of the disease. This may depend on the frequency of these abnormalities and, above all, the chronological sequence of those ones. In a mouse model of FHC, 25 cardiac histopathology and dysfunction of the mutated heterozygous mice recapitulated human HCM. Cardiac dysfunction including abnormal relaxation and reduced cardiac output preceded morphologic (left atrial enlargement) and histopathologic changes. The hypothesis was that altered mechanical properties in the mutant sarcomere directly caused cardiac dysfunction, before the occurrence of myocyte disarray, myocyte hypertrophy, and later fibrosis. Whether these findings do apply to human HCM or not remain unknown. Very few studies analysed the chronological sequence of abnormalities in families with HCM. Some data performed in small populations with TDI echocardiography suggested that functional abnormalities precede morphological abnormalities, 24, 26, 27 but areas of uncertainty persist and other studies found that sensitivity was in fact relatively low. 28 Additional studies are required to answer this question.
Conclusion
A 2D LVH score, using a new adjusted cut-off value, appears to be of great value for the diagnosis of HCM, especially in young adults and should therefore be proposed as an alternative diagnostic criterion to conventional ECG and echo criteria.
